Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-22

Ironwood Pharmaceuticals Inc (IRWD)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$1,948,390
Thomas McCourt total, FY2025
CEO pay percentile vs peers
CEO-to-median pay ratio
95.47%
Say-on-pay support, latest vote
Companies that benchmark against IRWD
22 companies name IRWD as a compensation peer

Each company listed discloses IRWD in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named IRWD in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Thomas McCourt$867,568$0$411,696$0$650,676$0$18,450$1,948,390
Chief Executive Officer
Tammi Gaskins474,7220447,7770274,440018,4501,215,389
Senior Vice President, Chief Commercial Officer
Gregory Martini470,4660447,7770274,440018,4501,211,133
Senior Vice President, Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Thomas McCourt$1,948,390$6,083,631−4,135,241
Tammi Gaskins1,215,389
Gregory Martini1,211,133

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Ronald SilverPFO & PAO2026-05-19A25,000$0$0CommonForm 4 ↗
Alexander DennerDirector2026-06-15A63,48100CommonForm 4 ↗
Alexander DennerDirector2026-06-15A4,06500CommonForm 4 ↗
Marla KesslerDirector2026-06-16A63,48100CommonForm 4 ↗
Jon DuaneDirector2026-06-16A63,48100CommonForm 4 ↗
Mark CurrieDirector2026-06-16A63,48100CommonForm 4 ↗
Julie McHughDirector2026-06-16D21,571480,460CommonForm 4 ↗
Jay ShepardDirector2026-06-16A63,48100CommonForm 4 ↗
Julie McHughDirector2026-06-16A63,48100CommonForm 4 ↗
Catherine MoukheibirDirector2026-06-16A63,48100CommonForm 4 ↗
Ronald SilverPFO & PAO2026-07-07D127,8905578,063CommonForm 4 ↗
Jeffrey SilberSVP, CMO, Head-Res&Drug2026-07-20A137,03600CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Tammi GaskinsRSU2025-01-01111,111$492,222
Gregory MartiniRSU2025-01-01111,111492,222
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Tammi Gaskins$492,222$0$00.0%
Gregory Martini492,222000.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Gregory MartiniPSU111,111$374,444
Tammi GaskinsPSU111,111374,444
Gregory MartiniPSU20,47569,001
Gregory MartiniPSU17,81060,020
Thomas McCourtPSU62,218209,675
Gregory MartiniPSU7,50025,275
Thomas McCourtPSU80,198270,267
Thomas McCourtOption442369.4
Thomas McCourtOption107284.2
Thomas McCourtOption205320.4
Thomas McCourtPSU540,0001,819,800
Thomas McCourtPSU132,438446,316
Tammi GaskinsPSU20,47569,001
Tammi GaskinsPSU17,81060,020
Thomas McCourtPSU176,584595,088
Tammi GaskinsPSU18,00060,660
Tammi GaskinsPSU8,48528,594
Gregory MartiniPSU4,24414,302
Thomas McCourtOption710225.6
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation philosophy emphasizes equity, and particularly performance-based equity, to strongly reinforce the principle of pay for performance and closely tie executive pay outcomes to stockholder value creation.

CEO STI target (% of salary)75%
CEO LTI target (% of salary)
Independent consultantAlpine Rewards LLC
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-16104,461,9364,958,394217,37495.47%Passed
20252025-06-10110,089,5763,511,07064,32596.91%Passed
20242024-06-18127,439,6877,953,50898,63794.13%Passed
20232023-06-20124,448,2712,240,534261,82798.23%Passed
20222022-06-01122,270,6763,391,424393,56697.3%Passed
20212021-06-02131,908,441780,9631,045,90899.41%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1695.47%a
20252025-06-1096.91%b
20242024-06-1894.13%c

a. Approved under the standard stated in the filing — “Any shares that are not voted, whether by abstention, broker non-votes or otherwise, will not affect the outcome of this proposal.”.

b. Approved under the standard stated in the filing — “Any shares that are not voted, whether by abstention, broker non-votes or otherwise, will not affect the outcome of this proposal.”.

c. Approved under the standard stated in the filing — “Any shares that are not voted, whether by abstention, broker non-votes or otherwise, will not affect the outcome of this proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)
CEO total compensation
Median employee compensation
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Julie McHughIndependent · Board Chair · Audit · Governance and Nominating$101,000$35,960$0$0$0$136,960
Catherine MoukheibirIndependent · Audit (Chair)75,00035,960000110,960
Andrew DreyfusIndependent · Compensation and HR (Chair) · Not standing for re-election · Departed during FY70,00035,960000105,960
Jon DuaneIndependent · Governance and Nominating · Compensation and HR (Chair)65,00035,960000100,960
Jay ShepardIndependent · Audit61,00035,96000096,960
Marla KesslerIndependent · Compensation and HR60,00035,96000095,960
Mark CurrieIndependent · Compensation and HR60,00035,96000095,960
Alexander DennerIndependent · Governance and Nominating (Chair)59,98435,96000095,944
Thomas McCourtEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$250,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)25,000 / 20,000 / 5,000
Stock ownership guideline3x annual retainer ($150,000)
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$551,984
Equity awards (grant-date value)$287,680
All other compensation$0
Total cost of the board$839,664

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Ironwood Pharmaceuticals Inc2025Thomas McCourt$867,568$411,696$0$650,676$1,948,390

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Thomas McCourtDEF 14A2026-04-280001104659-26-050325Section “Summary Compensation Table”. As printed: 1,948,390. Filing ↗machine: t29 · r1 · c48 · span 584182–584191
2Section 01, Tammi GaskinsDEF 14A2026-04-280001104659-26-050325Section “Summary Compensation Table”. As printed: 1,215,389. Filing ↗machine: r5 · c48 · span 605736–605745
3Section 01, Gregory MartiniDEF 14A2026-04-280001104659-26-050325Section “Summary Compensation Table”. As printed: 1,211,133. Filing ↗machine: r3 · c48 · span 594899–594908
4Section 03, Tammi Gaskins RSUDEF 14ASection “Executive Compensation” · grants of plan-based awards table.
5Section 03, Gregory Martini RSUDEF 14ASection “Executive Compensation” · grants of plan-based awards table.
6Section 07, pay ratio10-K2026-02-260001104659-26-020489Section “CEO Pay Ratio”. As printed: —. Filing ↗
7Section 08, Julie McHughDEF 14A2026-04-280001104659-26-050325Section “Director Compensation”. As printed: 136,960. Filing ↗machine: t15 · r6 · c24 · span 348093–348100
8Section 08, Catherine MoukheibirDEF 14A2026-04-280001104659-26-050325Section “Director Compensation”. As printed: 110,960. Filing ↗machine: t15 · r7 · c24 · span 351245–351252
9Section 08, Andrew DreyfusDEF 14A2026-04-280001104659-26-050325Section “Director Compensation”. As printed: 105,960. Filing ↗machine: t15 · r3 · c24 · span 339545–339552
10Section 08, Jon DuaneDEF 14A2026-04-280001104659-26-050325Section “Director Compensation”. As printed: 100,960. Filing ↗machine: t15 · r4 · c24 · span 342245–342252
11Section 08, Jay ShepardDEF 14A2026-04-280001104659-26-050325Section “Director Compensation”. As printed: 96,960. Filing ↗machine: t15 · r8 · c24 · span 354607–354613
12Section 08, Marla KesslerDEF 14A2026-04-280001104659-26-050325Section “Director Compensation”. As printed: 95,960. Filing ↗machine: t15 · r5 · c24 · span 345390–345396
13Section 08, Mark CurrieDEF 14A2026-04-280001104659-26-050325Section “Director Compensation”. As printed: 95,960. Filing ↗machine: t15 · r1 · c24 · span 333643–333649
14Section 08, Alexander DennerDEF 14A2026-04-280001104659-26-050325Section “Director Compensation”. As printed: 95,944. Filing ↗machine: t15 · r2 · c24 · span 336399–336405
15Section 08, Thomas McCourtDEF 14A2026-04-280001104659-26-050325Section “Director Compensation”. As printed: 0. Filing ↗
16Section 02, Ronald Silver 2026-05-19Form 42026-05-210001193125-26-234397Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Alexander Denner 2026-06-15Form 42026-06-170001193125-26-274279Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Alexander Denner 2026-06-15Form 42026-06-170001193125-26-274279Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Marla Kessler 2026-06-16Form 42026-06-170001193125-26-274292Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Jon Duane 2026-06-16Form 42026-06-170001193125-26-274283Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Mark Currie 2026-06-16Form 42026-06-170001193125-26-274288Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Julie McHugh 2026-06-16Form 42026-06-170001193125-26-274275Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Jay Shepard 2026-06-16Form 42026-06-170001193125-26-274301Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Julie McHugh 2026-06-16Form 42026-06-170001193125-26-274275Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Catherine Moukheibir 2026-06-16Form 42026-06-170001193125-26-274256Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Ronald Silver 2026-07-07Form 42026-07-090001193125-26-299749Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Jeffrey Silber 2026-07-20Form 42026-07-220001193125-26-312410Insider equity transaction reported since the proxy statement. Filing ↗
28Section 06, 2026 voteForm 8-K2026-06-180001104659-26-075730Item 5.07 · say-on-pay result. As reported: 95.47% (votes for as printed: 104,461,936). Filing ↗
29Section 06, 2025 voteForm 8-K2025-06-120001104659-25-058883Item 5.07 · say-on-pay result. As reported: 96.91% (votes for as printed: 110,089,576). Filing ↗
30Section 06, 2024 voteForm 8-K2024-06-210001104659-24-073736Item 5.07 · say-on-pay result. As reported: 94.13% (votes for as printed: 127,439,687). Filing ↗
31Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
32Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
33Section 09b board cost (computed)ComputedcomputedCash 551,984 + equity 287,680 + all other 0 = 839,664, summed across the director compensation table rows.machine: formula: Σ = 839,664
34Ironwood Pharmaceuticals Inc (subject), Section 10b CEO totalDEF 14A2026-04-280001104659-26-050325CEO total compensation as printed in Ironwood Pharmaceuticals Inc's own proxy. As printed: 1,948,390. Filing ↗machine: t29 · r1 · c48 · span 584182–584191